Several other analysts have also recently commented on the stock. Analysts at McNicoll Lewis & Vlak downgraded shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note to investors on Monday, February 25th. Separately, analysts at MLV Capital downgraded shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note to investors on Monday, February 25th. Finally, analysts at JPMorgan Chase initiated coverage on shares of Dynavax Technologies in a research note to investors on Wednesday, January 2nd. They set a “neutral” rating on the stock.
Dynavax Technologies traded down 7.32% on Monday, hitting $1.835. Dynavax Technologies has a 1-year low of $1.87 and a 1-year high of $5.34. The stock’s 50-day moving average is currently $2.93. The company’s market cap is $331.6 million.
Dynavax Technologies last announced its earnings results on Friday, March 1st. The company reported ($0.11) earnings per share for the quarter. The company had revenue of $1.80 million for the quarter, compared to the consensus estimate of $11.40 million. Analysts expect that Dynavax Technologies will post $-0.32 EPS for the current fiscal year.
Dynavax Technologies Corporation (Dynavax) is a biopharmaceutical company that discovers and develops products to prevent and treat infectious diseases, asthma and inflammatory and autoimmune diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.